Chemotherapy Pioneer Dies

Emil Frei III, a cancer researcher who in the 1950s combined multiple chemotherapy drugs to treat childhood leukemia, has died at the age of 89.

Written byDan Cossins
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Emil Frei IIISTEVE GILBERTOncologist Emil Frei III, who was one of the first scientists to use combination chemotherapy to treat cancer, died last week (May 4). He was 89.

When Frei began his career as a clinician and cancer researchers in the 1950s, chemotherapy drugs—many of which were derived from mustard gas—were seen as a last resort, reported The New York Times.

But together with his National Cancer Institute (NCI) colleague Emil Freireich and others, Frei began to explore the possibility of combining these cell-killing drugs to treat pediatric leukemia. This enabled the use of each drug in smaller quantities, they found, mitigating the toxic effects without reducing their combined potency on cancer cells.

At that time, childhood leukemia was almost always fatal. But a decade later, the approach codeveloped by Frei had boosted the 5-year survival rate to around 40 percent, reported the NYT. Today, pediatric leukemia has a long-term survival rate of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies